BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 08 Jun 2026
CJC-1295 and Ipamorelin: The GH Secretagogue Stack at the Centre of the 2026 Compounding Review
CJC-1295 and Ipamorelin are the most widely referenced growth hormone secretagogue combination in peptide research, but their regulatory status has been in flux for nearly three years. With their Category 2 nominations withdrawn as of April 2026 and the PCAC review scheduled for July 23–24, procurement teams need a clear picture of the pharmacology, the evidence landscape, and what the regulatory calendar means in practice.
Read briefing →
Research Pipeline
Thymosin Alpha-1: The Most Clinically Validated Research Peptide in the July 2026 PCAC Review
Thymosin alpha-1 (Tα1) holds a distinction no other research peptide can claim: it is approved as a prescription medicine in over 35 countries and has been evaluated in more than 11,000 human subjects across clinical trials. Yet it remains unapproved in the US and UK. With the FDA's Pharmacy Compounding Advisory Committee due to formally review the compound in July 2026, procurement teams need to understand what the evidence base actually shows — and what the regulatory inflection point means…
07 Jun 2026
Regulatory & Policy
FDA Proposes Permanent 503B Exclusion of GLP-1 Peptides: What the 30 June Deadline Means for Research and Procurement
The FDA's 30 April 2026 proposal to formally bar semaglutide, tirzepatide, and liraglutide from the 503B Bulks List closes the last major regulatory pathway for large-scale GLP-1 compounding. With the public comment window closing on 29–30 June 2026, UK and US research labs need to understand what this finalisation would mean for procurement, quality assurance, and parallel July 2026 developments on other peptides.
06 Jun 2026
Pharma & GLP-1
Parabilis Medicines Sets Terms for a $476M Nasdaq IPO — What the Helicon Peptide Platform Means for Oncology Research
Parabilis Medicines, formerly FogPharma, set terms this week for a Nasdaq IPO targeting up to $476M, backed by a freshly inked $2.2B milestone deal with Regeneron. Its Helicon stabilised helical peptide platform is designed to reach intracellular targets that have resisted three decades of drug development, with lead candidate zolucatetide posting a 100% disease-control rate in desmoid tumours.
05 Jun 2026
Research Pipeline
GLP-1 Peptides and the Nervous System: What the 2026 Evidence Landscape Means for Research Priorities
A comprehensive review published this week confirms that GLP-1 receptor agonists present a sharply divided neurological picture: semaglutide failed to slow Alzheimer's disease progression in the Phase 3 EVOKE trials, yet evidence in Parkinson's disease and stroke prevention remains meaningfully positive. For research labs procuring GLP-1 peptides, the distinction matters.
04 Jun 2026
Research Pipeline
BPC-157's Evidence Problem: What the New Investigation Means for Labs Ahead of the July PCAC Hearing
A joint Undark/STAT News investigation published this week laid out the thin and largely single-source evidentiary base behind BPC-157 — the peptide at the centre of the FDA's July 2026 compounding review. With the public comment window closing 9 July, research procurement teams need to understand what the science does and does not yet support.
03 Jun 2026
Reputational Risks
MHRA Turns Its Attention to UK Peptide Clinics: What the April 2026 Investigation Means for Legitimate Research Labs
The MHRA has opened investigations into UK clinics making therapeutic claims about unregulated peptide products, following a Guardian exposé and an earlier Criminal Enforcement Unit raid in Lincolnshire. For research-procurement professionals, the enforcement shift clarifies where regulatory tolerance ends — and why robust research-use-only labelling and sourcing discipline matter more than ever.
02 Jun 2026
Pharma & GLP-1
Regeneron's $2.3 Billion Bet on Helicon Peptides: What the Parabilis Deal Signals for the Peptide Research Landscape
Regeneron Pharmaceuticals announced a research collaboration with Parabilis Medicines on 18 May 2026, valued at up to $2.32 billion, centred on Helicons — stabilised, cell-penetrant alpha-helical peptides designed to reach intracellular targets that have long resisted conventional drug design. The deal crystallises a strategic shift in how institutional capital now views structurally engineered peptides, with implications extending well beyond oncology.
01 Jun 2026
Pharma & GLP-1
Orforglipron's ATTAIN-MAINTAIN Data Clarifies the Sequential GLP-1 Strategy — and Redraws Research Priorities for Peptide Labs
The ATTAIN-MAINTAIN trial, published in Nature Medicine on 12 May 2026, shows that switching from injectable GLP-1s to oral orforglipron (Foundayo) preserved roughly 75–80% of prior weight loss over 52 weeks. For research-procurement teams, the data crystallises a new sequential treatment paradigm — and raises pointed questions about which peptide and non-peptide reference compounds will be in demand next.
01 Jun 2026
Research Pipeline
Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review
Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.
01 Jun 2026
Regulatory & Policy
The PCAC July 2026 Hearing: What the Four Day-One Peptides — BPC-157, TB-500, KPV, and MOTS-c — Need to Prove Before the Review
On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee will evaluate BPC-157, TB-500, KPV, and MOTS-c for potential inclusion on the Section 503A Bulk Drug Substances List. With the oral-testimony registration deadline on 30 June and the cut-off for comments reaching the committee on 9 July, procurement teams have weeks — not months — to understand what is at stake.
01 Jun 2026
Pharma & GLP-1
Retatrutide's TRIUMPH-1 Phase 3 Data: 28.3% Weight Loss, a Pending NDA, and What It Means for Research Labs
Eli Lilly's triple agonist retatrutide delivered up to 28.3% average body-weight reduction at 80 weeks in the Phase 3 TRIUMPH-1 trial, with a 30.3% result at 104 weeks in a high-BMI sub-group. The data, released 21 May 2026, sets a new efficacy benchmark in the GLP-1 class — and is already intensifying procurement interest in research-grade retatrutide, despite the compound remaining strictly investigational and not compoundable under any current legal pathway.
30 May 2026